Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBT Margin (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBT Margin for 11 consecutive years, with 178.33% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 35972.0% to 178.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 295.89% through Dec 2025, down 21549.0% year-over-year, with the annual reading at 296.17% for FY2025, 21575.0% down from the prior year.
  • EBT Margin hit 178.33% in Q4 2025 for Voyager Therapeutics, up from 208.07% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1523.23% in Q4 2022 to a low of 3239.97% in Q1 2022.
  • Historically, EBT Margin has averaged 578.6% across 5 years, with a median of 300.7% in 2021.
  • Biggest five-year swings in EBT Margin: tumbled -284665bps in 2022 and later skyrocketed 332287bps in 2023.
  • Year by year, EBT Margin stood at 18.02% in 2021, then soared by 8353bps to 1523.23% in 2022, then plummeted by -96bps to 63.5% in 2023, then plummeted by -947bps to 538.06% in 2024, then surged by 67bps to 178.33% in 2025.
  • Business Quant data shows EBT Margin for VYGR at 178.33% in Q4 2025, 208.07% in Q3 2025, and 641.67% in Q2 2025.